Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Aldoxorubicin + ALT-803 + Avelumab + Cisplatin + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6301 + haNK cells + Paclitaxel|
|Synonyms||NANT non-small cell lung cancer vaccine combination|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ALT-803||N-803|N803|Nogapendekin alfa|ALT803||ALT-803 (Nogapendekin alfa) is a fusion protein consisting a mutant IL-15 and a soluble IL-15Ra Fc, which activates and converts memory CD8+ T cells to effector immune cells with antitumor activity (PMID: 24404427, PMID: 31338557).|
|Aldoxorubicin||INNO-206|Doxorubicin-EMCH||Chemotherapy - Anthracycline 13||Aldoxorubicin (Doxorubicin-EMCH) is a derivative prodrug of doxorubicin that is converted to free doxorubicin within the acidic environment within tumors, and once converted, doxorubicin intercalates DNA, inhibits DNA synthesis and induces apoptosis (PMID: 30936721).|
|Avelumab||Bavencio||MSB0010718C||Immune Checkpoint Inhibitor 151 PD-L1/PD-1 antibody 98||Bavencio (avelumab) is a monoclonal antibody binds to human immunosuppressive ligand programmed death-ligand 1 (PD-L1, CD274) and blocks protein signaling, resulting in immune regulation and antitumor immunity (PMID: 26014098). Bavencio (avelumab) is FDA-approved for use in adult and pediatric patients of 12 years or older with metastatic Merkel cell carcinoma, as maintenance therapy in locally advanced or metastatic urothelial carcinoma (UC), in locally advanced or metastatic UC that progressed following chemotherapy, and in combination with axitinib as first-line therapy in advanced renal cell carcinoma (FDA.gov).|
|Cisplatin||Platinol||CDDP||Chemotherapy - Platinum 7||Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary).|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 16||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|ETBX-011||ETBX 011|ETBX011||ETBX-011 is an engineered adenoviral vaccine encoding human carcinoembryonic antigen that may stimulate anti-tumor immunity (Journal of Clinical Oncology 32, no. 15_suppl (May 2014) 3093-3093, PMID: 31594913).|
|ETBX-051||ETBX051|ETBX 051||ETBX-051 is a virally based vaccine that infects cells and induces expression of the brachyury protein protein, which may activate the immune system to elicit a cytotoxic T-lymphocyte (CTL) response against brachyury expressing tumor cells (PMID: 31594913).|
|ETBX-061||ETBX061|ETBX 061||ETBX-061 is a virally based vaccine that infects cells and causes expression of the Muc1 protein, which may activate the immune system to elicit a cytotoxic T-lymphocyte (CTL) response against Muc1 expressing tumor cells (PMID: 31594913).|
|Fluorouracil||Adrucil||5-FU||Chemotherapy - Antimetabolite 14||Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent, which interferes with DNA and RNA synthesis thereby preventing cancer cell growth and is FDA approved for colorectal, breast, stomach, and pancreatic cancer (FDA.gov).|
|GI-4000||GI 4000|GI4000||RAS Inhibitor (Pan) 8||GI-4000 vaccine elicits an immune response by stimulating a specific cytotoxic T-cell response against the mutated forms of Ras (PMID: 29528991).|
|GI-6301||GI-6301 is a cancer vaccine that activates immune response against tumor cells (PMID: 26130065).|
|Paclitaxel||Taxol||7-Epipaclitaxel||Antimicrotubule Agent 14 BCL2 Family Inhibitor 6||Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).|
|haNK cells||CD16.158V ER IL-2|NK-92 cells||haNK cells are natural killer cells, specifically from the NK-92 cell line, that have been engineered to express IL-2 and the CD16 allele, and when combined with other therapies such as an immunotherapy can synergistically enhance antibody-dependent cell-mediated cytotoxicity (PMID: 28477372).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03574649||Phase II||Carboplatin + Cisplatin + Docetaxel + Paclitaxel Aldoxorubicin + ALT-803 + Avelumab + Cisplatin + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6301 + haNK cells + Paclitaxel||QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer||Withdrawn||USA||0|